← Back to Search

Behavioural Intervention

Telemedicine for Skin Cancer Diagnosis

N/A
Waitlist Available
Led By David Polsky, MD, PhD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have 1-3 lesions for evaluation
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up end of the study (4 weeks)
Awards & highlights

Study Summary

This trial is looking at whether a telemedicine platform can increase access to expert skin cancer diagnostic services, which could improve outcomes for people in underserved areas.

Who is the study for?
This trial is for adults over 18 with 1-3 skin lesions that need checking, but not on the scalp, mouth, lips, genitalia, nails, eyes or inside the ear. It's aimed at improving skin cancer diagnosis through telemedicine to help those in areas without easy access to expert evaluations.Check my eligibility
What is being tested?
The SpotCheck study compares remote diagnostic tools (Dermlite Cam and Nevisense 3.0) against traditional in-person evaluation including a skin biopsy for detecting skin cancer. The goal is to see if telemedicine can match the accuracy of face-to-face doctor visits.See study design
What are the potential side effects?
Potential side effects may include discomfort or minor bleeding from biopsy procedures and possible anxiety or stress related to using new technology for health assessments.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have 1 to 3 specific areas that need to be checked.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~end of the study (4 weeks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and end of the study (4 weeks) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Agreement Between Telemedicine and In-Person Treatment Recommendation
Secondary outcome measures
False-Negative Rate of In-Person Evaluation
False-Negative Rate of Telemedicine Evaluation
False-Positive Rate of In-Person Evaluation
+9 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Participants with skin lesionsExperimental Treatment3 Interventions
Participants who have up to 3 concerning skin lesions will be evaluated by both an in-person dermatologist and a team of three teledermatologists(board-certified dermatologists). The teledermatoogy team will deliver a consensus recommendation. If either the in-person dermatologist or teledermatologists are concerned that the skin spot(s) may be a skin cancer, a biopsy will be recommended and can be performed at no charge. Or if both agree that the spot(s) are not concerning for skin cancer, no biopsy will be needed.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Skin biopsy
2016
Completed Phase 4
~940
Dermlite Cam
2020
N/A
~150
Nevisense 3.0
2020
N/A
~150

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,358 Previous Clinical Trials
816,664 Total Patients Enrolled
David Polsky, MD, PhDPrincipal InvestigatorNYU Langone Health
1 Previous Clinical Trials
138 Total Patients Enrolled

Media Library

Enhanced Telemedicine (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT04411810 — N/A
Skin Cancer Research Study Groups: Participants with skin lesions
Skin Cancer Clinical Trial 2023: Enhanced Telemedicine Highlights & Side Effects. Trial Name: NCT04411810 — N/A
Enhanced Telemedicine (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04411810 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies in this research project?

"That is accurate. According to the information on clinicaltrials.gov, this clinical trial was initially posted on August 20th 2020 and continues to search for individuals to participate in it. 500 participants are required at 1 location before the study can be completed."

Answered by AI

How many participants are being recruited for this trial?

"Indeed, clinicaltrials.gov indicates that this trial is still in progress and recruiting participants. It initially launched on August 20th 2020, with the most recent edit of May 6th 2022. The aim is to enlist 500 patients from one medical centre."

Answered by AI

Is the participant pool for this research restricted to those aged 40 or younger?

"This medical trial only permits participants who are aged between 18 and 89. There exists dozens of other trials for younger/older patients, with 11 that cater to those under 18 years old and 160 for people over 65."

Answered by AI

Could I participate in this medical experiment if I met the requirements?

"This medical trial seeks 500 participants suffering from cutaneous malignancy aged between 18 and 89. Eligibility requirements include being 18 years of age or older, as well as possessing 1-3 lesions that can be examined."

Answered by AI
~33 spots leftby Mar 2025